



# Nevada PEBP

FY2024

Prepared by Client Analytics

Cynthia Eaton ([cynthia.eaton@express-scripts.com](mailto:cynthia.eaton@express-scripts.com))

9/13/2024



*\*The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes.*

Hello PEBP Team,

This is the FY24 Summary File for the three State of Nevada PEBP plans (CDHP, EPO, and PPO). The summary contains Trend breakouts for each plan (Utilization, Unit Cost, and Cost Share). Along with the most notable changes of drugs within the top moving indications. Each plan breakout has a peer comparison of Trend. The file concludes with several Key Statistics of the three plans in aggregate.

### **CDHP Overall Trend Summaries:**

<b>CDHP Overall Trend</b>		<b>% Change</b>
<b>Current Period - Plan Cost Net PMPM</b>	<b>\$77.25</b>	
Utilization	\$2.79	4.0%
Unit Cost	\$3.88	5.5%
Member Share	\$0.04	0.1%
<b>Total Change in Plan Cost Net PMPM</b>	<b>\$6.71</b>	<b>9.5%</b>
<b>Previous Period - Plan Cost Net PMPM</b>	<b>\$70.54</b>	

Top moving indications and most notable drug changes within the indications are as follows:

- **Cancer:** Previous ranked 2<sup>nd</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
  - Plan Cost Net ↓ \$768k (18.4%) to current \$3.4m.
  - Plan Cost Net PMPM ↓ \$.88 (7.0%) to current \$11.76.
  - Patient Count ↓ 3 to current count of 246.
  - Adjusted Rxs ↓ 113 to current count of 1,881.
- **Notable Drug Changes within Indication:**
  - **Revlimid:**
    - Previous ranked 1<sup>st</sup>, currently ranked 9<sup>th</sup> by Plan Cost Net.
    - Plan Cost Net ↓ \$379k (71.0%) to current \$155k.
    - Plan Cost Net PMPM ↓ \$1.08 (66.9%) to current \$.53.
    - Patient Count ↓ 2 to current count of 2.
    - Adjusted Rxs ↓ 20 to current count of 13.
  - **Brukinsa:**
    - Previous ranked 25<sup>th</sup>, currently ranked 4<sup>th</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$218k (2147.0%) to current \$228k.
    - Plan Cost Net PMPM ↑ \$.75 (2462.0%) to current \$.79.
    - Patient Count ↑ 1 to current count of 2.
    - Adjusted Rxs ↑ 18 to current count of 19.

- **Unureg:**
  - Previous ranked 14<sup>th</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$210k (175.6%) to current \$330k.
  - Plan Cost Net PMPM ↑ \$.78 (214.2%) to current \$1.14.
  - Patient Count: Remains at 1.
  - Adjusted Rxs ↑ 8 to current count of 15.
  
- **Lenalidomide (Generic for Revlimid):**
  - Previous ranked 8<sup>th</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$149k (67.2%) to current \$372k.
  - Plan Cost Net PMPM ↑ \$.61 (90.6%) to current \$1.28.
  - Patient Count: Remains at 3.
  - Adjusted Rxs ↑ 12 to current count of 29.
  
- **Vaccinations:** Previous ranked 7<sup>th</sup>, currently ranked 5<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$393k (50.1%) to current \$1.2m.
  - Plan Cost Net PMPM ↑ \$1.69 (71.2%) to current \$4.06.
  - Patient Count ↓ 1,956 to current count of 5,273.
  - Adjusted Rxs ↓ 2,623 to current count of 10,214.
  
- **Notable Drug Changes within Indication:**
  - **Comirnaty 2023-2024 (COVID):**
    - New, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$275k.
    - Plan Cost Net PMPM: New, current \$.95.
    - Patient Count: New, current count of 1,884.
    - Adjusted Rxs: New, current count of 1,929.
  
  - **Spikevax 2023-2024 (COVID):**
    - New, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$206k.
    - Plan Cost Net PMPM: New, current \$.71.
    - Patient Count: New, current count of 1,329.
    - Adjusted Rxs: New, current count of 1,354.
  
  - **Arexvy (RSV):**
    - New, currently ranked 3<sup>rd</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$160k.
    - Plan Cost Net PMPM: New, current \$.55.
    - Patient Count: New, current count of 591.
    - Adjusted Rxs: New, current count of 590.

- **Ophthalmic Conditions:** Previous ranked 21<sup>st</sup>, currently ranked 9<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$498k (210.4%) to current \$735k.
  - Plan Cost Net PMPM ↑ \$1.82 (253.9%) to current \$2.54.
  - Patient Count ↓ 35 to current count of 365.
  - Adjusted Rxs ↑ 26 to current count of 942.
  
- **Notable Drug Changes within Indication:**
  - **Tepezza:**
    - Previous ranked 2<sup>nd</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$396k (686.5%) to current \$453k.
    - Plan Cost Net PMPM ↑ \$1.39 (796.8%) to current \$1.56.
    - Patient Count: Remains at 1.
    - Adjusted Rxs ↑ 7 to current count of 8.
  
  - **Eylea:**
    - Previous ranked 1<sup>st</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$58k (55.3%) to current \$163k.
    - Plan Cost Net PMPM ↑ \$.24 (77.0%) to current \$.56.
    - Patient Count ↑ 5 to current count of 17.
    - Adjusted Rxs ↑ 39 to current count of 98.
  
  - **Oxervate:**
    - New, currently ranked 3<sup>rd</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$76k.
    - Plan Cost Net PMPM: New, current \$.26.
    - Patient Count: New, current count of 1.
    - Adjusted Rxs: New, current count of 4.

#### Peer Comparison:

- Peer: ESI CDH Program
- PEBP CDHP is outperforming the peer.
- Peer experienced Plan Cost Net PMPM of \$80.91 compared to CDHP PEBP of \$77.25.
- Peer experienced Trend of 11.6%, compared to CDHP PEBP Trend of 9.5%.

## EPO Overall Trend Summaries:

EPO Overall Trend		% Change
<b>Current Period - Plan Cost Net PMPM</b>	<b>\$178.45</b>	
Utilization	\$8.79	5.7%
Unit Cost	\$13.44	8.8%
Member Share	\$3.23	2.1%
<b>Total Change in Plan Cost Net PMPM</b>	<b>\$25.46</b>	<b>16.6%</b>

**Previous Period - Plan Cost Net PMPM** **\$152.99**

Top moving indications and most notable drug changes within the indications are as follows:

- **Diabetes:** Previous ranked 2<sup>nd</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$246k (15.7%) to current \$1.8m.
  - Plan Cost Net PMPM ↑ \$6.07 (30.0%) to current \$26.28.
  - Patient Count ↓ 25 to current count of 647.
  - Adjusted Rxs ↑ 104 to current count of 11,514.
- **Notable Drug Changes within Indication:**
  - **Ozempic:**
    - Previous ranked 1<sup>st</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$161k (40.5%) to current \$560k.
    - Plan Cost Net PMPM ↑ \$2.89 (57.8%) to current \$8.15.
    - Patient Count ↑ 15 to current count of 157.
    - Adjusted Rxs ↑ 298 to current count of 1,230.
  - **Mounjaro:**
    - Previous ranked 3<sup>rd</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$177k (111.5%) to current \$335k.
    - Plan Cost Net PMPM ↑ \$2.82 (137.6%) to current \$4.87.
    - Patient Count ↑ 32 to current count of 91.
    - Adjusted Rxs ↑ 325 to current count of 664.
  - **Trulicity:**
    - Previous ranked 2<sup>nd</sup>, currently ranked 3<sup>rd</sup> by Plan Cost Net.
    - Plan Cost Net ↓ \$80k (32.0%) to current \$171k.
    - Plan Cost Net PMPM ↓ \$.77 (23.6%) to current \$2.49.
    - Patient Count ↓ 18 to current count of 53.
    - Adjusted Rxs ↓ 206 to current count of 401.

- **Endocrine Disorders:** Previous ranked 3<sup>rd</sup>, currently ranked 3<sup>rd</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$230k (19.0%) to current \$1.4m.
  - Plan Cost Net PMPM ↑ \$5.28 (33.7%) to current \$20.94.
  - Patient Count ↓ 6 to current count of 31.
  - Adjusted Rxs ↓ 4 to current count of 234.
  
- **Notable Drug Changes within Indication:**
  - **Korlym:**
    - Previous ranked 1<sup>st</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$201k (17.8%) to current \$1.3m.
    - Plan Cost Net PMPM ↑ \$4.73 (32.4%) to current \$19.35.
    - Patient Count: Remains at 2.
    - Adjusted Rxs ↑ 6 to current count of 23.
  
  - **Other drug changes in this indication were not notable.**
  
- **Gout:** Previous ranked 44<sup>th</sup>, currently ranked 16<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$160k (888.1%) to current \$178k.
  - Plan Cost Net PMPM ↑ \$2.36 (1010.0%) to current \$2.59.
  - Patient Count ↓ 9 to current count of 127.
  - Adjusted Rxs ↓ 5 to current count of 1,096.
  
- **Notable Drug Changes within Indication:**
  - **Krystexxa:**
    - New, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$162k.
    - Plan Cost Net PMPM: New, current \$2.35
    - Patient Count: New, current count of 2.
    - Adjusted Rxs: New, current count of 4.
  
  - **Other drug changes in this indication were not notable.**

**Peer Comparison:**

- Government – West Region/SaveOn (custom peer created for PEBP EPO plan)
- The peer is outperforming PEBP EPO.
- Peer experienced Plan Cost Net PMPM of \$106.99 compared to PEBP EPO of \$178.45
- Peer experienced Trend of 11.5%, compared to PEBP EPO of 16.6%

## PPO Overall Trend Summaries:

PPO Overall Trend		% Change
<b>Current Period - Plan Cost Net PMPM</b>	<b>\$103.31</b>	
Utilization	\$2.75	3.3%
Unit Cost	\$14.74	17.5%
Member Share	\$1.67	2.0%
<b>Total Change in Plan Cost Net PMPM</b>	<b>\$19.16</b>	<b>22.8%</b>

**Previous Period - Plan Cost Net PMPM** **\$84.15**

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:** Previous ranked 1<sup>st</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$1.5m (54.3%) to current \$4.3m.
  - Plan Cost Net PMPM ↑ \$2.47 (15.3%) to current \$18.69.
  - Patient Count ↑ 77 to current count of 279.
  - Adjusted Rxs ↑ 717 to current count of 2,576.
- **Notable Drug Changes within Indication:**
  - **Stelara:**
    - Previous ranked 3<sup>rd</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$316k (113.9%) to current \$593k.
    - Plan Cost Net PMPM ↑ \$.96 (59.8%) to current \$2.57.
    - Patient Count ↑ 5 to current count of 14.
    - Adjusted Rxs ↑ 49 to current count of 131.
  - **Skyrizi Pen:**
    - Previous ranked 4<sup>th</sup>, currently ranked 3<sup>rd</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$161k (75.1%) to current \$376k.
    - Plan Cost Net PMPM ↑ \$.38 (30.9%) to current \$1.63.
    - Patient Count ↑ 3 to current count of 13.
    - Adjusted Rxs ↑ 40 to current count of 110.
  - **Rinvoq:**
    - Previous ranked 7<sup>th</sup>, currently ranked 5<sup>th</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$239k (196.6%) to current \$360k.
    - Plan Cost Net PMPM ↑ \$.86 (121.6%) to current \$1.56.
    - Patient Count ↑ 11 to current count of 16.
    - Adjusted Rxs ↑ 75 to current count of 115.

- **Diabetes:** Previous ranked 2<sup>nd</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$1.7m (89.6%) to current \$3.7m.
  - Plan Cost Net PMPM ↑ \$4.73 (41.6%) to current \$16.08.
  - Patient Count ↑ 530 to current count of 1,582.
  - Adjusted Rxs ↑ 8,439 to current count of 23,829.
  
- **Notable Drug Changes within Indication:**
  - **Ozempic:**
    - Previous ranked 1<sup>st</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$582k (109.8%) to current \$1.1m.
    - Plan Cost Net PMPM ↑ \$1.75 (56.8%) to current \$4.83.
    - Patient Count ↑ 148 to current count of 355.
    - Adjusted Rxs ↑ 1,211 to current count of 2,491.
  
  - **Mounjaro:**
    - Previous ranked 3<sup>rd</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$697k (350.1%) to current \$896k.
    - Plan Cost Net PMPM ↑ \$2.73 (350.1%) to current \$3.89.
    - Patient Count ↑ 143 to current count of 236.
    - Adjusted Rxs ↑ 1,356 to current count of 1,780.
  
  - **Other drug changes in this indication were not notable.**
  
- **Enzyme Deficiencies:** Previous ranked 6<sup>th</sup>, currently ranked 4<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$1m (158.2%) to current \$1.7m.
  - Plan Cost Net PMPM ↑ \$3.46 (92.9%) to current \$7.18.
  - Patient Count ↑ 3 to current count of 7.
  - Adjusted Rxs ↑ 29 to current count of 52.
  
- **Notable Drug Changes within Indication:**
  - **Nexviazyme:**
    - Previous ranked 2<sup>nd</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$608k (313.4%) to current \$803k.
    - Plan Cost Net PMPM ↑ \$2.36 (208.9%) to current \$3.49.
    - Patient Count: Remains at 1.
    - Adjusted Rxs ↑ 8 to current count of 12.



- **Galafold:**
  - New, currently ranked 3rd by Plan Cost Net.
  - Plan Cost Net: New, current \$237k.
  - Plan Cost Net PMPM: New, current \$1.03.
  - Patient Count: New, current count of 1.
  - Adjusted Rxs: New, current count of 8.
  
- **Palnziq:**
  - Previous ranked 4<sup>th</sup>, currently ranked 4<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$131k (1059.1%) to current \$144k.
  - Plan Cost Net PMPM ↑ \$.55 (766.0%) to current \$.62.
  - Patient Count: Remains at 1.
  - Adjusted Rxs ↑ 9 to current count of 10.

**Peer Comparison:**

- Government – West Region/SaveOn (custom peer created for PEBP PPO plan)
- PEBP PPO is outperforming the peer.
- Peer experienced Plan Cost Net PMPM of \$106.99 compared to PEBP PPO of \$103.31
- Peer experienced Trend of 11.5%, compared to PEBP PPO of 22.8%

Total Overall Trend		% Change
<b>Current Period - Plan Cost Net PMPM</b>	<b>\$99.27</b>	
Utilization	\$2.89	3.4%
Unit Cost	\$8.94	10.4%
Member Share	\$1.86	2.2%
<b>Total Change in Plan Cost Net PMPM</b>	<b>\$13.69</b>	<b>16.0%</b>
<b>Previous Period - Plan Cost Net PMPM</b>	<b>\$85.58</b>	

**Summary of Total** – Overall the main driver of Trend was Specialty Utilization driven by an increase of 11.5% in Specialty patients. This resulted in a 18.7% increase in Specialty Days of Therapy.

Overall Trend was mitigated by increased rebates of 36.0%. This produced a negative Unit Cost Trend of (4.0%) on Specialty drugs and reduced Non-Specialty Unit Cost Trend to 11.8%, combined Unit Cost Trend is 10.4%.

Member Cost contributed to Trend on both Non-Specialty and Specialty drugs: NSP 3.1%, SP 1.4%. This is due to Drug Mix on Non-Specialty drugs, which was primary driven by utilization of more expensive brand drugs.

**Key Statistics:**

Nevada PEBP Total			
Description	FY24	FY23	Change
Average Members per Month	49,065	48,303	1.6%
Number of Unique patients	37,636	38,417	-2.0%
Members Utilizing the Benefit	76.7%	79.5%	-2.8
Gross Cost/Adjusted Rx	\$103.50	\$93.38	10.8%
Plan Spend	\$88,157,729	\$71,454,594	23.4%
Rebates (estimated)	\$29,710,201	\$21,849,300	36.0%
Plan Cost Net	\$58,447,528	\$49,605,295	17.8%
Plan Cost Net PMPM	\$99.27	\$85.58	16.0%
Non-Specialty Plan Cost Net PMPM	\$45.91	\$38.87	18.1%
Specialty Plan Cost Net PMPM	\$53.36	\$46.71	14.2%
Generic Fill Rate	87.0%	85.9%	1.0
90 Day Utilization	60.3%	61.5%	-1.2
Retail - Maintenance 90 Utilization	28.7%	28.6%	0.1
Home Delivery Utilization	31.6%	33.0%	-1.4
Member Cost Net %	24.4%	25.8%	-1.4

END OF REPORT